Pierre Fabre. Company presentation September 7th 2011

Transcription

1 Pierre Fabre Company presentation September 7th 2011

2 Who We Are: A French medium-sized pharmaceutical company looking for partners for research and development of added value, efficient and innovative pharmaceutical and dermocosmetic products Industrial drugstore activities in three fields : Medicine, Family Health, Dermocosmetics and Dermatology Putting innovation at the heart of its process 1500 employees in R&D, Expenditure in R&D 2010 : 210 million Patents : portfolio of 3500 patents 2

3 Targeted Market & Competition: Three areas of priority research Oncology, CNS and Dermocosmetics & Dermatology Oncology: More than half of the R&D budget is invested in the search for innovative solutions to fight cancer Two major area of work : small molecules and monoclonal antibodies intended as anti-cancerous Central nervous system: Treatment of psychosis and chronic pain Dermocosmetic and dermatology: Prevent, cure, embellish whilst respecting pharmaceutical rigor and quality Medical dermatology group: Glytone, Ducray, PF Dermatologie Phytodermatology group : Elancyl, Aderma, Klorane Avene Galenic Rene Furterer Miscellaneous: 7 areas in Family Healthcare: Immunity, tobacco addiction, women's health, movement, infectious diseases, skin care and oral hygiene 3

4 Unique Selling Proposition (1/2): Marine microorganisms, a source of rare active substances Creation in 2001 with University of Pierre et Marie Curie (Paris VI) and the CNRS (National Centre of Scientific Research) of a joint research team at the Oceanology Observatory of Banyuls sur mer Study of marine microorganisms, a sustainable biological source of original active substances and contribution of a better characterisation of this poorly understood biodiversity Collection of more than 1,500 different species registered at the World Federation of Cultures Collection High-throughput screening (HTS) of marine organism extracts for bioactive secondary metabolites derived from: Marine sponges Marine-derived steptomyces Marine bacteria Algae 4

5 Unique Selling Proposition (2/2): A real willingness to collaborate with Academic partners, Biotech companies and Big Pharmas Academic partners: R&D collaborative programs Joint Research Units with public institutions Biotech companies: Fee-for-service Agreements Research programs through public grants In-licensing agreements Big Pharmas: Out-licensing partners Co-development and marketing strategies 5

6 Objectives & Expectations: Build partnerships with public or private organizations to create value in dermocosmetics & dermatology Public institutions or private companies: Providing exclusive products which could exhibit valuable properties for possible use in cosmetics and personal care Respecting a chain of quality and expertise ( control of the marine ingredient production) In keeping with sustainable development: respect of the principles laid down for protecting biodiversity Specific needs in dermocosmetics and dermatology: Various status: Drug, medical devices, cosmetic ingredient Active ingredients in Atopic dermatitis, sensitive skin, psoriasis, acne, wound healing, whitening and anti-aging Functional ingredients : emollients, surfactants, thickener, preservatives (in relation with new Cosmetic products regulations, REACH, medias hypes) Natural and natural derived raw materials 6

7 Advantage in collaborating with us: Gaining manufacturing capabilities and geographic extension A streamlined management structure: A quick decision process Human relationships based on trust Quick access to skills from research to industrialisation Innovative and cutting-edge technologies Best in class know-how Differential clinical products Focused strong marketing representation 7

8 Thank you for your attendence Contact : philippe.catroux@pierre-fabre.com 8